Variation in the fibroblast growth factor 23 (FGF23) gene associates with serum FGF23 and bone strength in infants

被引:1
|
作者
Enlund-Cerullo, Maria [1 ,2 ,3 ,4 ]
Holmlund-Suila, Elisa [1 ,2 ,4 ]
Valkama, Saara [1 ,2 ,4 ]
Hauta-alus, Helena [1 ,2 ,4 ,5 ,6 ,7 ]
Rosendahl, Jenni [1 ,2 ,4 ]
Andersson, Sture [1 ,2 ]
Pekkinen, Minna [1 ,2 ,3 ,4 ]
Makitie, Outi [1 ,2 ,3 ,4 ,8 ,9 ]
机构
[1] Univ Helsinki, Childrens Hosp, Pediat Res Ctr, Helsinki, Finland
[2] Helsinki Univ Hosp, Childrens Hosp, Pediat Res Ctr, Helsinki, Finland
[3] Folkhalsan Inst Genet, Folkhalsan Res Ctr, Helsinki, Finland
[4] Univ Helsinki, Fac Med, Res Program Clin & Mol Metab, Helsinki, Finland
[5] Natl Inst Hlth & Welf THL, Publ Hlth Res, Helsinki, Finland
[6] Oulu Univ Hosp, PEDEGO Res Unit, MRC Oulu, Oulu, Finland
[7] Univ Oulu, PEDEGO Res Unit, MRC Oulu, Oulu, Finland
[8] Karolinska Univ Hosp, Dept Mol Med & Surg, Stockholm, Sweden
[9] Karolinska Univ Hosp, Karolinska Inst, Ctr Mol Med, Clin Genet, Stockholm, Sweden
基金
瑞典研究理事会; 芬兰科学院;
关键词
FGF23; genetic variation; vitamin D; bone strength; infants (0-24 months); DOMINANT HYPOPHOSPHATEMIC RICKETS; PHYSIOLOGICAL-ROLE; MINERAL DENSITY; VITAMIN-D; PHOSPHATE; MUTATIONS; CHILDREN;
D O I
10.3389/fgene.2023.1192368
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Introduction: The effects of genetic variation in fibroblast growth factor 23 (FGF23) are unclear. This study explores the associations of single-nucleotide polymorphisms (SNPs) of FGF23 with phosphate and vitamin D metabolism and bone strength in early childhood. Methods: The study is part of the vitamin D intervention in infant (VIDI) trial (2013-2016), in which healthy term infants born to mothers of Northern European origin received vitamin D-3 supplementation of 10 or 30 mu g/day from 2 weeks to 24 months of age (ClinicalTrials.gov NCT01723852). Intact and C-terminal FGF23 (cFGF23), 25-hydroxyvitamin D (25-OHD), parathyroid hormone, phosphate, and peripheral quantitative computed tomography (pQCT)-derived bone strength parameters were analyzed at 12 and 24 months. The study included 622 VIDI participants with genotyping data on FGF23 SNPs rs7955866, rs11063112, and rs13312770. Results: Rs7955866 minor allele homozygotes had lowest cFGF23 at both time-points (mixed model for repeated measurements, p(variant) = 0.009). Minor alleles of rs11063112 were associated with a greater age-related decrease in phosphate concentration (p(interaction) = 0.038) from 12 to 24 months. Heterozygotes of rs13312770 had the greatest total bone mineral content (total BMC), cross-sectional area (total CSA), and polar moment of inertia (PMI) at 24 months (ANOVA p = 0.005, 0.037, and 0.036, respectively). Rs13312770 minor alleles were associated with a greater increase of total BMC, but a smaller increase of total CSA and PMI, during follow-up (p(interaction) <0.001, 0.043, and 0.012, respectively). Genotype of FGF23 did not modify 25-OHD. Conclusion: The study finds that genetic variation in FGF23 modifies cFGF23, phosphate, and pQCT-derived bone strength parameters from 12 to 24 months of age. These findings potentially promote an understanding of the regulation of FGF23 and its role in bone metabolism and temporal changes thereof during early childhood.
引用
收藏
页数:18
相关论文
共 50 条
  • [11] Role of Fibroblast Growth Factor 23 (FGF23) and αKlotho in Cancer
    Ewendt, Franz
    Feger, Martina
    Foeller, Michael
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 8
  • [12] PKC regulates the production of fibroblast growth factor 23 (FGF23)
    Baer, Ludmilla
    Hase, Philipp
    Foeller, Michael
    PLOS ONE, 2019, 14 (03):
  • [13] SERUM AND VASCULAR FIBROBLAST GROWTH FACTOR 23 (FGF23) ARE ASSOCIATED WITH VASCULAR CALCIFICATION
    Donate-Correa, J. J.
    Martin-Nunez, E.
    Hernandez-Carballo, C.
    Ferri, C. M.
    Arevalo-Gomez, M.
    Gonzalez-Luis, A.
    Rodriguez-Ramos, S.
    Cerro-Lopez, P.
    Lopez-Castillo, A.
    Delgado-Molinos, A.
    Mora-Fernandez, C.
    Navarro-Gonzalez, J. F.
    ATHEROSCLEROSIS, 2021, 331 : E94 - E94
  • [14] Regulation of fibroblast growth factor 23 (FGF23) in health and disease
    Baer, Ludmilla
    Stournaras, Christos
    Lang, Florian
    Foeller, Michael
    FEBS LETTERS, 2019, 593 (15) : 1879 - 1900
  • [15] Fibroblast growth factor 23 (FGF23) promotes prostate cancer growth
    Chow, A.
    Trebinjac, S.
    Emmenegger, U.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S41 - S41
  • [16] Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men
    Arezoo Daryadel
    Carla Bettoni
    Thomas Haider
    Pedro H. Imenez Silva
    Udo Schnitzbauer
    Eva Maria Pastor-Arroyo
    Roland H. Wenger
    Max Gassmann
    Carsten A. Wagner
    Pflügers Archiv - European Journal of Physiology, 2018, 470 : 1569 - 1582
  • [17] Calcineurin inhibitors regulate fibroblast growth factor 23 (FGF23) synthesis
    Baer, Ludmilla
    Grossmann, Claudia
    Gekle, Michael
    Foeller, Michael
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2017, 390 (11) : 1117 - 1123
  • [18] Calcineurin inhibitors regulate fibroblast growth factor 23 (FGF23) synthesis
    Ludmilla Bär
    Claudia Großmann
    Michael Gekle
    Michael Föller
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2017, 390 : 1117 - 1123
  • [19] Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men
    Daryadel, Arezoo
    Bettoni, Carla
    Haider, Thomas
    Silva, Pedro H. Imenez
    Schnitzbauer, Udo
    Pastor-Arroyo, Eva Maria
    Wenger, Roland H.
    Gassmann, Max
    Wagner, Carsten A.
    PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2018, 470 (10): : 1569 - 1582
  • [20] Glucocorticoids dexamethasone and prednisolone suppress fibroblast growth factor 23 (FGF23)
    Martina Feger
    Franz Ewendt
    Jörg Strotmann
    Holger Schäffler
    Daniela Kempe-Teufel
    Philipp Glosse
    Gabriele I. Stangl
    Michael Föller
    Journal of Molecular Medicine, 2021, 99 : 699 - 711